Justine L. Kuiper

Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer

R. Jonas A. Nilsson, Niki Karachaliou, Jordi Berenguer et al. · Oncotarget · 2015 · 199 citations · Full text

Treatment and survival of patients with EGFR -mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis

Justine L. Kuiper, Lizza Hendriks, Anthonie J. van der Wekken et al. · Lung Cancer · 2015 · 131 citations · Full text

Medicine, Retrospective Cohort Analysis, Pathology +8

Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment

Adrianus J. de Langen, M. Jebbink, Sayed M.S. Hashemi et al. · British Journal of Cancer · 2018 · 45 citations · Full text

Rationale and Study Design of the IRENE-Trial (NVALT-16): A Phase II Trial to Evaluate Iressa Rechallenge in Advanced NSCLC Patients With an Activating EGFR Mutation Who Responded to an EGFR-TKI Used As First-Line or Previous Treatment

Justine L. Kuiper, Daniëlle A.M. Heideman, Tom Würdinger et al. · Clinical Lung Cancer · 2014 · 13 citations · Full text

Phase Ii Trial, Iressa Rechallenge, Clinical Trials +6

Trastuzumab and paclitaxel in patients (pts) with EGFR mutated non-small-cell lung cancer (NSCLC) that express HER2 after progression on EGFR TKI treatment.

J. De Langen, Justine L. Kuiper, Erik Thunnissen et al. · Journal of Clinical Oncology · 2017 · 12 citations

Pathology, Tumor Biopsy, Egfr Tki Treatment +16